Everything below concerns GLP-1 receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-16. Numbers and descriptions here follow the published literature rather than marketing material.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Prussian blue or "ferric ferrocyanide", Fe4[Fe(CN)6]3, is an old and well-known iron-cyanide complex, extensively used as pigment and in several other applications. Its formation can be used as a simple wet chemistry test to distinguish between aqueous solutions of Fe2+ and Fe3+ as they react (respectively) with potassium ferricyanide and potassium ferrocyanide to form Prussian blue. Another old example of an organoiron compound is iron pentacarbonyl, Fe(CO)5, in which a neutral iron atom is bound to the carbon atoms of five carbon monoxide molecules. The compound can be used to make carbonyl iron powder, a highly reactive form of metallic iron. Thermolysis of iron pentacarbonyl gives triiron dodecacarbonyl, Fe3(CO)12, a complex with a cluster of three iron atoms at its core. Collman's reagent, disodium tetracarbonylferrate, is a useful reagent for organic chemistry; it contains iron in the −2 oxidation state. Cyclopentadienyliron dicarbonyl dimer contains iron in the rare +1 oxidation state.
=== Musculoskeletal examination of congenital muscular dystrophies === Muscle fibrosis and Joint contractures or fixed deformities are cardinal clinical signs of congenital muscular dystrophies. Muscle fibrosis and shortening eventually lead to joint contractures or fixed deformities. They are important to the diagnosis of CMD. However, some patients initially present with joint laxity. Joint deformities can occur in the extremities and spine. Severe deformities can result in joint dislocation and walking difficulties or gait abnormalities. However, the specific pattern of muscle involvement in each of the CMD subtypes is not fully elucidated. A recent review identified CMD subtype-specific clinical patterns of muscle and Joint involvement which could be of help to the differential diagnosis of CMD subtypes. This was especially true for Merosin-deficient congenital muscular dystrophy (MDC1A) or LAMA2-related CMD subtype. Nonetheless, these muscle and Joint patterns of involvement have to be correlated with other clinical signs, neuro-imaging reports, muscle biopsy immune-staining and molecular or genetic analysis results, whenever available. This comprehensive approach is critical for the correct and timely diagnosis of CMDs.
Dense irregular connective tissue is a form of dense connective tissue characterized by collagen fibers that appear randomly interwoven instead of forming parallel bundles as in dense regular connective tissue. Dense irregular connective tissue has less ground substance than loose connective tissue. Fibroblasts are the predominant cell type, scattered sparsely across the tissue.
thiol 1. Any of a class of organosulfur compounds consisting of a sulfur atom attached to a hydrogen atom and any other organic substituent, with the general formula R–SH. Thiols are the sulfur analogues of alcohols. Also thiol derivative and mercaptan. 2. The –SH functional group itself. Also sulfhydryl, sulfanyl, and mercapto.
=== PirB and visual plasticity === Paired-immunoglobulin-like receptor B (PirB), an MHCI-binding receptor, is involved in the regulation of visual plasticity. PirB is expressed in the central nervous system and diminishes ocular dominance plasticity in the developmental critical period and adulthood. When the function of PirB was abolished in mutant mice, ocular dominance plasticity became more pronounced at all ages. PirB loss of function mutant mice also exhibited enhanced plasticity after monocular deprivation during the critical period. These results suggest that PirB may be involved in the modulation of synaptic plasticity in the visual cortex.
Sources: en.wikipedia.org
== Awards and honors == Wilhelm Exner Medal, 1958 Johann Josef Ritter von Precht Medal of TU wien, 1965 Erwin Schrödinger Prize of the Austrian Academy of Sciences, 1970 M.S. Tswett Chromatography Award, 1974 (first year awarded) Commemorative M.S. Tswett Medal of the U.S.S.R. Academy of Sciences, 1978 Honorary degree from the Technische Universität Berlin First-class cross of the Austrian Order for Science and Art A Street in Munich was called after her (Erika-Cremer-Straße in 81829 München)
Supercritical drying Supercritical drying is reputed to be the most efficient drying technique but is rather expensive and difficult to implement. It was first implemented by Canham in 1994 and involves superheating the liquid pore above the critical point to avoid interfacial tension.
Tazarotene, sold under the brand name Tazorac, among others, is a third-generation prescription topical retinoid. It is primarily used for the treatment of plaque psoriasis and acne. Tazarotene is also used as a therapeutic for photoaged and photodamaged skin. It is a member of the acetylenic class of retinoids. Tazarotene was approved for medical use in 1997 and is available as a generic medication.
Profile at Parliament of the United Kingdom Contributions in Parliament at Hansard Voting record at Public Whip Record in Parliament at TheyWorkForYou Profile on OpenSanctions, an open database of sanctions and persons of interest HAND ID – Their entry in the HAND (Human and Digital) Talent ID registry of real people and fictional characters George Galloway Contributor page, The Guardian website George Galloway Contributor page, The Independent website Hansard 1803–2005: contributions in Parliament by George Galloway George Galloway at IMDb
Sources: en.wikipedia.org
==== Xbox reception ==== The Xbox edition received mixed reviews from critics in comparison to the original game. On the topic of graphics, Matthew Kato from Game Informer wrote that there were "graphical updates here and there" and mentioned the game's inclusion of weather. Greg Kasavin of GameSpot felt that the visuals weren't extraordinary and not enough to make the game "good-looking". IGN's Aaron Boulding mentioned that they were "the biggest disappointment". He commented that the environments were noteworthy in design, but "not in their overall look and level of detail". The AI technology was a surplus for the Xbox edition, because of critics praising for its human-like behavior. Kato mentioned that the bot AI contained some "human-esque traits" and that it would start to understand the map after some rounds. Kasavin found it surprising that the bots weren't following real-life tactics of terrorists or counter-terrorists, but rather mimic the actions of a player. He pointed out that they would camp at a certain place and follow the orders of a player, such as following them or holding a position. Many critics also highlighted Xbox Live as one of the main reasons to purchase the game. Kasavin noted that it runs properly, with hosted matches able to hold 10 players. Boulding expressed that "online play over Xbox Live is going to be the greatest reason to buy this game" and that it's convenient.
Cholecystokinin tetrapeptide (CCK-4, tetragastrin, Trp-Met-Asp-Phe-NH2) is a peptide fragment derived from the larger peptide hormone cholecystokinin. Unlike cholecystokin which has a variety of roles in the gastrointestinal system as well as central nervous system effects, CCK-4 acts primarily in the brain as an anxiogenic, although it does retain some GI effects, but not as much as CCK-8 or the full length polypeptide CCK-58. CCK-4 reliably causes severe anxiety symptoms when administered to humans in a dose of as little as 50 μg, and is commonly used in scientific research to induce panic attacks for the purpose of testing new anxiolytic drugs. Since it is a peptide, CCK-4 must be administered by injection, and is rapidly broken down once inside the body so has only a short duration of action, although numerous synthetic analogues with modified properties are known.
=== Confusion with tin and antimony === Since the Bronze Age, metallurgists and engineers have understood the difference between rare and valuable tin, essential for alloying with copper to produce tough and corrosion resistant bronze, and 'cheap and cheerful' lead. However, the nomenclature in some languages is similar. Romans called lead plumbum nigrum ("black lead"), and tin plumbum candidum ("bright lead"). The association of lead and tin can be seen in other languages: the word olovo in Czech translates to "lead", but in Russian, its cognate олово (olovo) means "tin". To add to the confusion, lead bore a close relation to antimony: both elements commonly occur as sulfides (galena and stibnite), often together. Pliny incorrectly wrote that stibnite would give lead on heating, instead of antimony. In countries such as Turkey and India, the originally Persian name surma (Persian: سرمه) came to refer to either antimony sulfide or lead sulfide, and in some languages, such as Russian, gave its name to antimony (сурьма).
=== 2010–2012: Early growth === Blockchain analysts estimate that Nakamoto had mined about one million bitcoins before he disappeared in 2010 and handed the network alert key and control of the code repository over to Gavin Andresen. Andresen later became lead developer at the Bitcoin Foundation, an organization founded in September 2012 to promote bitcoin. After early "proof-of-concept" transactions, the first major users of bitcoin were black markets, such as the dark web Silk Road. During its 30 months of existence, beginning in February 2011, Silk Road exclusively accepted bitcoins as payment, transacting ₿9.9 million, worth about $214 million.
Edward Frank Gale. For political service. Richard Gallagher. For services to the community in Aberdeen. Lucy Gannon, Writer. For services to Television Drama. Richard Ian Gardner. For services to the Police. Arthur Buchan Geddes, Sector Officer, the Coastguard Agency, Department of Transport. Arthur Samuel George, School Crossing Patrol, Portsmouth, Hampshire. For services to Road Safety. James Alexander George, Administrative Officer, Ministry of Defence. Graham James Gibb, Leader, Grampian Police and Braemar Mountain Rescue Teams. For services to Mountain Rescue. Alison Gray Gibson, Temporary Project Manager, Royal Mail, Edinburgh. For services to the Post Office. Sydney Gibson, Secretary, Fergusons Lane Tenants Association. For services to the community in Scotswood, Newcastle-upon-Tyne. Valerie Gibson. For services to the Right to Peace and Quiet Campaign. Joan Giddings, lately Office Administrator, British Apparel and Textile Confederation. For services to the Clothing Industry. Elizabeth Glasgow. For services to the community in Wester Hailes, Edinburgh. John Glover. For services to Golf. Maureen Audrey Gobbett, Higher Executive Officer, Ministry of Defence. Major Douglas George Goddard. For services to the community in Wargrave-on-Thames, Berkshire. David William Goodall. For services to Nature Conservation in Hampshire. Ian Kenmure Evans-Gordon. For political service. Stephen Goulding, Pay Band 8, the Employment Service, Department for Education and Employment. Anne Greaves. For services to the Health and Safety Commission's Occupational Health Advisory Committee.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。